000027087 000__ 01322cam\a2200421\i\4500
000027087 001__ 27087
000027087 003__ SzGeWIPO
000027087 005__ 20230630132602.0
000027087 008__ 071205s2013    enk|||||r|||| 00| 0 eng d
000027087 035__ $$a(wipo)0
000027087 035__ $$a(OCoLC)1161759955
000027087 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000027087 041__ $$aeng
000027087 050_4 $$aK1401.A15$$bJ675
000027087 08204 $$a346.048$$222
000027087 084__ $$aGB 137
000027087 1001_ $$aHashim, Mohamed R.,$$eauthor.
000027087 24510 $$aAccess denied :$$ba review and critique of the Patented Medicines (Notice of Compliance) Regulations /$$cM.R. Hashim.
000027087 264_1 $$aOxford [England] :$$bOxford University Press,$$c2013.
000027087 300__ $$a1 volume ;$$c[28] cm.
000027087 336__ $$atext$$btxt$$2rdacontent
000027087 337__ $$aunmediated$$bn$$2rdamedia
000027087 338__ $$avolume$$bnc$$2rdacarrier
000027087 4901_ $$aJournal Of Intellectual Property Law & Practice,$$x1747-1532 ;$$vJanuary 2013, Vol 8, No 1, pages 23 - 32
000027087 650_0 $$aIntellectual property.
000027087 650_0 $$aIntangible property.
000027087 650_0 $$aIntellectual property$$zCanada.
000027087 650_0 $$aPatents$$zCanada.
000027087 650_4 $$aPharmaceuticals
000027087 650_4 $$aPatents$$zCanada
000027087 651_0 $$aCanada$$xCommerce$$xLaw and legislation.
000027087 830_0 $$aJournal Of Intellectual Property Law & Practice ;$$vJanuary 2013, Vol 8, No 1, pages 23 - 32.
000027087 8564_ $$uhttp://dx.doi.org/10.1093/jiplp/jps186$$y[For WIPO staff only]
000027087 903__ $$aJournal of Intellectual Property Law & Practice.
000027087 942__ $$cART$$jGB 137 Jan 2013 Vol 8 No 1$$2ddc
000027087 952__ $$w2013-05-06$$p2013-0141$$u41566$$bMAIN$$10$$kGB 137$$v2013-05-06$$zTagged$$71$$cLibrary
000027087 980__ $$aBIB
000027087 999__ $$c29491$$d29491